Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy

Won Hyuk Choi, Sungsoo Kim, Woo Jin Hyung, Jeong Sik Yu, Chan Il Park, Seung Ho Choi, Sung Hoon Noh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In the treatment of recurrent or metastatic gastrointestinal stromal tumors (GIST), good prognoses may not be expected by surgery alone. Recently, imatinib has been applied for the treatment of GISTs, resulting in improved patient survival. However, long-term success is limited due to the development of resistance. Herein, we report two cases of long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. A 49 year-old man was diagnosed to a duodenal GIST with single hepatic metastasis, and an antrectomy including the duodenal lesion with intraoperative radiofrequency ablation were performed in April, 2002. After four months, a new metastatic hepatic lesion was identified. Percutaneous radiofrequency ablation was done, and imatinib therapy was started. A 56 year-old man underwent laparoscopic segmental resection of the distal ileum and partial excision of parietal peritoneum in March, 2001 to treat a malignant GIST of the distal ileum that was attached to parietal peritoneum. After six months, recurrence of GIST with peritoneal seeding and hepatic metastasis was found, and he underwent cytoreductive surgery including right hemicolectomy and wedge resection of liver. After surgery, there was no residual tumor grossly and imatinib therapy was started. In both cases, they were doing well with no evidence of recurrence for 5 years with imatinib therapy. Therefore, in patients with a recurrent GIST, improved survival can be expected with imatinib therapy after cytoreductive surgery.

Original languageEnglish
Pages (from-to)437-440
Number of pages4
JournalYonsei medical journal
Volume50
Issue number3
DOIs
Publication statusPublished - 2009 Jul 30

Fingerprint

Gastrointestinal Stromal Tumors
Liver
Peritoneum
Ileum
Therapeutics
Neoplasm Metastasis
Recurrence
Survival
Residual Neoplasm
Imatinib Mesylate

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Choi, Won Hyuk ; Kim, Sungsoo ; Hyung, Woo Jin ; Yu, Jeong Sik ; Park, Chan Il ; Choi, Seung Ho ; Noh, Sung Hoon. / Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. In: Yonsei medical journal. 2009 ; Vol. 50, No. 3. pp. 437-440.
@article{92c19be5147c4471a0dbd3ad69f1ac22,
title = "Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy",
abstract = "In the treatment of recurrent or metastatic gastrointestinal stromal tumors (GIST), good prognoses may not be expected by surgery alone. Recently, imatinib has been applied for the treatment of GISTs, resulting in improved patient survival. However, long-term success is limited due to the development of resistance. Herein, we report two cases of long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. A 49 year-old man was diagnosed to a duodenal GIST with single hepatic metastasis, and an antrectomy including the duodenal lesion with intraoperative radiofrequency ablation were performed in April, 2002. After four months, a new metastatic hepatic lesion was identified. Percutaneous radiofrequency ablation was done, and imatinib therapy was started. A 56 year-old man underwent laparoscopic segmental resection of the distal ileum and partial excision of parietal peritoneum in March, 2001 to treat a malignant GIST of the distal ileum that was attached to parietal peritoneum. After six months, recurrence of GIST with peritoneal seeding and hepatic metastasis was found, and he underwent cytoreductive surgery including right hemicolectomy and wedge resection of liver. After surgery, there was no residual tumor grossly and imatinib therapy was started. In both cases, they were doing well with no evidence of recurrence for 5 years with imatinib therapy. Therefore, in patients with a recurrent GIST, improved survival can be expected with imatinib therapy after cytoreductive surgery.",
author = "Choi, {Won Hyuk} and Sungsoo Kim and Hyung, {Woo Jin} and Yu, {Jeong Sik} and Park, {Chan Il} and Choi, {Seung Ho} and Noh, {Sung Hoon}",
year = "2009",
month = "7",
day = "30",
doi = "10.3349/ymj.2009.50.3.437",
language = "English",
volume = "50",
pages = "437--440",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. / Choi, Won Hyuk; Kim, Sungsoo; Hyung, Woo Jin; Yu, Jeong Sik; Park, Chan Il; Choi, Seung Ho; Noh, Sung Hoon.

In: Yonsei medical journal, Vol. 50, No. 3, 30.07.2009, p. 437-440.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy

AU - Choi, Won Hyuk

AU - Kim, Sungsoo

AU - Hyung, Woo Jin

AU - Yu, Jeong Sik

AU - Park, Chan Il

AU - Choi, Seung Ho

AU - Noh, Sung Hoon

PY - 2009/7/30

Y1 - 2009/7/30

N2 - In the treatment of recurrent or metastatic gastrointestinal stromal tumors (GIST), good prognoses may not be expected by surgery alone. Recently, imatinib has been applied for the treatment of GISTs, resulting in improved patient survival. However, long-term success is limited due to the development of resistance. Herein, we report two cases of long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. A 49 year-old man was diagnosed to a duodenal GIST with single hepatic metastasis, and an antrectomy including the duodenal lesion with intraoperative radiofrequency ablation were performed in April, 2002. After four months, a new metastatic hepatic lesion was identified. Percutaneous radiofrequency ablation was done, and imatinib therapy was started. A 56 year-old man underwent laparoscopic segmental resection of the distal ileum and partial excision of parietal peritoneum in March, 2001 to treat a malignant GIST of the distal ileum that was attached to parietal peritoneum. After six months, recurrence of GIST with peritoneal seeding and hepatic metastasis was found, and he underwent cytoreductive surgery including right hemicolectomy and wedge resection of liver. After surgery, there was no residual tumor grossly and imatinib therapy was started. In both cases, they were doing well with no evidence of recurrence for 5 years with imatinib therapy. Therefore, in patients with a recurrent GIST, improved survival can be expected with imatinib therapy after cytoreductive surgery.

AB - In the treatment of recurrent or metastatic gastrointestinal stromal tumors (GIST), good prognoses may not be expected by surgery alone. Recently, imatinib has been applied for the treatment of GISTs, resulting in improved patient survival. However, long-term success is limited due to the development of resistance. Herein, we report two cases of long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. A 49 year-old man was diagnosed to a duodenal GIST with single hepatic metastasis, and an antrectomy including the duodenal lesion with intraoperative radiofrequency ablation were performed in April, 2002. After four months, a new metastatic hepatic lesion was identified. Percutaneous radiofrequency ablation was done, and imatinib therapy was started. A 56 year-old man underwent laparoscopic segmental resection of the distal ileum and partial excision of parietal peritoneum in March, 2001 to treat a malignant GIST of the distal ileum that was attached to parietal peritoneum. After six months, recurrence of GIST with peritoneal seeding and hepatic metastasis was found, and he underwent cytoreductive surgery including right hemicolectomy and wedge resection of liver. After surgery, there was no residual tumor grossly and imatinib therapy was started. In both cases, they were doing well with no evidence of recurrence for 5 years with imatinib therapy. Therefore, in patients with a recurrent GIST, improved survival can be expected with imatinib therapy after cytoreductive surgery.

UR - http://www.scopus.com/inward/record.url?scp=67651165286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651165286&partnerID=8YFLogxK

U2 - 10.3349/ymj.2009.50.3.437

DO - 10.3349/ymj.2009.50.3.437

M3 - Article

C2 - 19568608

AN - SCOPUS:67651165286

VL - 50

SP - 437

EP - 440

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -